Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma

Cancer Research

Volumn 61, Issue 10, 2001, Pages 4143-4154

  Shi, Qian ^a   Le, Xiangdong ^a   Abbruzzese, James L ^a   Peng, Zhihai ^b   Qian, Chao Nan ^a,c   Tang, Huamei ^b   Xiong, Qinghua ^a   Wang, Bailiang ^a   Li, Xiang Chen ^d   Xie, Keping ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR SP1; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RNA ANALYSIS; TUMOR VASCULARIZATION;

ADENOCARCINOMA; DNA-BINDING PROTEINS; ENDOTHELIAL GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOKINES; PANCREATIC NEOPLASMS; PROMOTER REGIONS (GENETICS); RESPONSE ELEMENTS; RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR; SP3 TRANSCRIPTION FACTOR; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035872399     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Cancer of the pancreas
2. Role of growth factors in pancreatic cancer
3. Advances from genetic clues in pancreatic cancer
4. Angiogenesis and angiogenesis inhibition: An overview
5. Vascular endothelial growth factor is a secreted angiogenic mitogen
6. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
7. Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine
8. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression
9. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo
10. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
11. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
12. Halting angiogenesis suppresses carcinoma cell invasion
13. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
14. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
15. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence
16. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo
17. An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells
18. Vascular endothelial growth factor is essential for corpus luteum angiogenesis
19. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
20. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor
21. In vitro neutralization of vascular endothelial growth factor activation of FLK-1 by a monoclonal antibody
22. Flk-1 as a target for tumor growth inhibition
23. Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies
24. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
25. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
26. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia
27. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells: Identification of a 5′ enhancer
28. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes
29. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms
30. Identification of a human VPF/VEGF 3′ untranslated region mediating hypoxia-induced mRNA stability
31. Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I
32. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression
33. Induction of vascular endothelial growth factor gene expression by interleukin-1β in rat aortic smooth muscle cells
34. Interleukin-6 induces the expression of vascular endothelial growth factor
35. Constitutive and inducible interleukin-8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic
36. Regulation of vascular endothelial growth factor expression in cultured keratinocytes - Implications for normal and impaired wound healing
37. Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression
38. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells
39. Induction of vascular endothelial growth factor by tumor necrosis factor α in human glioma cells: Possible roles of SP-1
40. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing
41. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development
42. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1α and developmentally expressed in blood vessels
43. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: Implications for translation under hypoxia
44. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription
45. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression
46. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein
47. Von Hippel-Lindau disease
48. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein
49. Putative control of angiogenesis in hemangioblastomas by the von Hippel-Lindau tumor suppressor gene
50. The von Hippel-Lindau tumor-suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity
51. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein
52. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways
53. Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells
54. Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma
55. Heterogeneity of potential for hematogenous metastasis in a human pancreatic carcinoma
56. Sp-1 binds promoter elements regulated by the RB protein and Sp-1-mediated transcription is stimulated by RB coexpression
57. Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells
58. Mutant ras oncogenes up-regulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
59. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression
60. Activator-protein-1 binding potentiates the hypoxia-inducible factor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells
61. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: Control of hypoxia-inducible factor-1 activity by nitric oxide
62. Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids
63. Lipopolysaccharide enhances the production of vascular endothelial growth factor by human pulp cells in culture
64. Oncogenes as inducers of tumor angiogenesis
65. VEGF expression in an osteoblast-like cell line is regulated by a hypoxia response mechanism
66. Hypoxia-induced transcriptional activation of vascular endothelial growth factor is inhibited by serum
67. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
68. Cobalt stimulates the expression of vascular endothelial growth factor mRNA in rat cardiac cells
69. Hypoxia-induced transcription of the vascular endothelial growth factor gene is independent of functional AP-1 transcription factor
70. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression
71. Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: Evidence against a regulatory role for Src kinase
72. Loss of PTEN facilitates HIF-1-mediated gene expression
73. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts
74. Transcriptional regulation of vascular endothelial growth factor gene expression in ovarian bovine granulosa cells
75. Transforming growth factor-α-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation
76. The Sp-family of transcription factors
77. Functional analyses of the transcription factor Sp4 reveal properties distinct from Sp1 and Sp3
78. An inhibitor domain in Sp3 regulates its glutamine-rich activation domains
79. Sp3 is a bifunctional transcription regulator with modular independent activation and repression domains
80. Sp3 and Sp4 can repress transcription by competing with Sp1 for the core cis-elements on the human ADH5/FDH minimal promoter
81. Transcription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence
82. Sp1 binding is inhibited by (m)Cp(m)CpG methylation
83. The retinoblastoma gene product RB stimulates Sp1-mediated transcription by liberating Sp1 from a negative regulator